Anti-aging medicine has long been a small specialty field of practice culturally adjacent to sports medicine, but considerably less rigorous and more derided by the mainstream. The present development of a longevity industry, based on means to slow and reverse aspects of aging conclusively demonstrated in laboratory animals and now slowly making their way towards the clinic, is going to have interesting effects on the field of anti-aging medicine. Over some period of time, anti-aging medicine will become reputable, a field in which physicians manage the delivery of treatments for aging that actually work. The field will swell to become the majority of all medical practice, as the majority of all serious illness and death is age-related.
Initially, this growth and takeover of mainstream medicine will look fairly prosaic, as it will likely occur in advance of the availability of any very impressive therapies. It will be built on lifestyle choice, weight management, and calorie restriction mimetic drugs like rapamycin, and the involvement of governments will be driven primarily by the desire to reduce the burden of ever expanding entitlement spending in an aging population. The really interesting therapies and outcomes will arrive later, finding a system ready and waiting for them. As an example of what this early transition will look like, one might read today's open access position paper on the Italian health system, proposing the changes needed for an effective focus on aging.
Towards integration of healthspan strategies into the Italian National Health Service
Italy currently ranks among the world's oldest nations, with adults aged ≥65 years accounting for 24.1% of the population - the highest proportion in the EU - and a projected median age of 51 years by 2050. While life expectancy at birth reaches 85.4 years for women and 81.4 for men, Healthy Life Years amount to only 69.6 and 68.5, respectively, documenting a substantial lifespan-healthspan divide. The prevalence of multimorbidity and disability exceeds 60% in adults aged ≥75 years; women bear a disproportionate share of this burden, both as patients and as caregivers. Meanwhile, the Italian National Health Service (Servizio Sanitario Nazionale, SSN) remains hospital-centric, regionally fragmented, and predominantly reactive, with prevention accounting for a historically modest share of total expenditure.
Against this background, longevity medicine is an emerging, prevention-oriented discipline that aims to extend healthspan - defined here as the portion of life lived in good health, with preserved physical and cognitive function and without significant disability or multimorbidity. It integrates multi-omic biomarkers, digital monitoring, adaptive trial methodology, and life-course risk stratification within a translational framework. Although most constituent tools remain at an exploratory or surrogate stage, and clinical utility has yet to be established, the emphasis on early intervention and precision prevention offers potential to reduce the accumulation of age-related disease and ease long-term pressure on the SSN.
This position paper analyzes Italy's demographic and epidemiological trajectory, examines the structural constraints of the SSN, and outlines the scientific foundations of longevity medicine. It advocates for multidisciplinary translational research and identifies five strategic investment priorities: (i) clinically validated biomarkers of biological age; (ii) interoperable digital monitoring platforms; (iii) Bayesian adaptive multimodal trials; (iv) explainable-AI risk stratification tools; and (v) longevity-informed curricula in medical training. These proposals should be regarded as a staged agenda for evaluation; their relevance will depend on whether they deliver measurable gains in patient-relevant outcomes, feasibility, and cost-effectiveness within the SSN.
View the full article at FightAging
